BUZZ-Ultragenyx profits from selling a U.S. FDA voucher worth $210 millions
路透社2026/10/07 14:16October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87 ** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash ** The company received the voucher after FDA approval of its drug Genglycos (link) for treating Glycogen Storage Disease Type Ia (also known as von Gierke disease) ** According to the licensing agreement, upon completion of the transaction, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health ** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet replied ** The recommended retail price per patient for Genglycos in the U.S. is $2.7 million ** As of the previous trading day’s close, the stock had fallen about 35% year to date (In order to facilitate non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be erroneous or lack required context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation tools.)
October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87
** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash
** The company obtained this voucher after the FDA approved its drug Genglycos (link) for the treatment of type Ia glycogen storage disease (also known as Von Gierke disease)
** According to the licensing agreement, after the deal is completed, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health
** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet responded
** The recommended retail price of Genglycos in the United States is $2.7 million per patient
** As of the close of the previous trading day, the stock had fallen about 35% year to date
(To support non-native English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be inaccurate or lack necessary context, and Reuters does not guarantee the accuracy of the translated text. The automated translations are provided solely for reader convenience. Reuters accepts no responsibility for any harm or loss caused by the use of its automated translation service.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Coca-Cola FEMSA Shares Rise After JPMorgan Upgrade
Bank of Canada: Inflation-growth tradeoff keeps policy on hold – RBC
Data: If ETH breaks above $2,537, the cumulative short liquidation intensity on major CEXs will reach $862 millions.
Strategic oil reserves near record lows and still to be tapped! The United States plans to provide up to 17 million barrels of crude oil.
Data released this week show that the size of the US Strategic Petroleum Reserve is only about 13 million barrels less than its original scale when the reserve system was established. The US Department of Energy's recent call for companies to participate in crude oil exchange programs is part of the action following the March agreement among IEA member countries to release a total of 400 million barrels from their reserves this year. At that time, the US pledged to release 172 million barrels from its strategic reserves, but there has been limited participation from companies in the exchanges since then. Analysts believe that recent supply disruptions caused by hurricanes and other factors may prompt the US government to make further use of its reserves.
Crypto prices
More
